Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY® (nipocalimab-aahu),c ...
Integrating motivational interviewing with cognitive behavioral therapy improves long-term patient improvement rates than CBT alone, results of a five-year, randomized clinical trial of a new combined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results